Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline in Pediatric Rifampin-Resistant Tuberculosis
NCT02906007Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2017
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of bedaquiline in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2017; status: completed.
02
Drugs
bedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02906007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906007.